SI1474416T1 - Derivati dihidrobenzodiazepin-2-ona za zdravljenje nevroloskih motenj - Google Patents

Derivati dihidrobenzodiazepin-2-ona za zdravljenje nevroloskih motenj

Info

Publication number
SI1474416T1
SI1474416T1 SI200331034T SI200331034T SI1474416T1 SI 1474416 T1 SI1474416 T1 SI 1474416T1 SI 200331034 T SI200331034 T SI 200331034T SI 200331034 T SI200331034 T SI 200331034T SI 1474416 T1 SI1474416 T1 SI 1474416T1
Authority
SI
Slovenia
Prior art keywords
dihydrobenzodiazepin
derivatives
treatment
neurological disorders
neurological
Prior art date
Application number
SI200331034T
Other languages
English (en)
Slovenian (sl)
Inventor
Geo Adam
Erwin Goetschi
Juergen Wichmann
Thomas Johannes Woltering
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SI1474416T1 publication Critical patent/SI1474416T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SI200331034T 2002-02-06 2003-01-28 Derivati dihidrobenzodiazepin-2-ona za zdravljenje nevroloskih motenj SI1474416T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02002012 2002-02-06
PCT/EP2003/000859 WO2003066623A1 (en) 2002-02-06 2003-01-28 Dihydrobenzodiazepin-2-one derivatives for the treatment of neurological disorders
EP03702549A EP1474416B1 (en) 2002-02-06 2003-01-28 Dihydrobenzodiazepin-2-one-derivatives for the treatment of neurological disorders

Publications (1)

Publication Number Publication Date
SI1474416T1 true SI1474416T1 (sl) 2008-02-29

Family

ID=27675598

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200331034T SI1474416T1 (sl) 2002-02-06 2003-01-28 Derivati dihidrobenzodiazepin-2-ona za zdravljenje nevroloskih motenj

Country Status (30)

Country Link
US (1) US6949542B2 (https=)
EP (1) EP1474416B1 (https=)
JP (1) JP4077411B2 (https=)
KR (1) KR20040081486A (https=)
CN (1) CN100497333C (https=)
AR (1) AR038481A1 (https=)
AT (1) ATE374196T1 (https=)
AU (1) AU2003205695B8 (https=)
BR (1) BR0307474A (https=)
CA (1) CA2474219C (https=)
DE (1) DE60316538T2 (https=)
DK (1) DK1474416T3 (https=)
ES (1) ES2294264T3 (https=)
GT (1) GT200300028A (https=)
HR (1) HRP20040678A2 (https=)
IL (1) IL163102A (https=)
MX (1) MXPA04007516A (https=)
MY (1) MY176608A (https=)
NO (1) NO327697B1 (https=)
NZ (1) NZ534122A (https=)
PA (1) PA8565901A1 (https=)
PE (1) PE20031011A1 (https=)
PL (1) PL372425A1 (https=)
PT (1) PT1474416E (https=)
RU (1) RU2315764C2 (https=)
SI (1) SI1474416T1 (https=)
TW (1) TWI326599B (https=)
UY (1) UY27654A1 (https=)
WO (1) WO2003066623A1 (https=)
ZA (1) ZA200406032B (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2386980C (en) * 1999-10-15 2010-03-16 Geo Adam Benzodiazepine derivatives for use in acute or chronic neurological disorders
AU2004262897B9 (en) * 2003-07-25 2009-12-17 F. Hoffmann-La Roche Ag Combination of mGluR2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders
AU2006298829B2 (en) 2005-09-27 2011-03-03 F. Hoffmann-La Roche Ag Oxadiazolyl pyrazolo-pyrimidines as mGluR2 antagonists
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
BRPI0810655A2 (pt) * 2007-04-19 2014-11-04 Hoffmann La Roche Derivados de di-hidro-benzo[b][1,4] diazepin-2-ona sulfonamida
EP2188263B1 (en) 2007-08-27 2012-06-27 F. Hoffmann-La Roche AG Benzimidazole derivatives used as fxr agonists
PL2203439T3 (pl) 2007-09-14 2011-06-30 Addex Pharmaceuticals Sa 1',3'-dipodstawione-4-fenylo-3,4,5,6-tetrahydro-2H, 1'H-[1, 4']bipirydynylo-2'-ketony
US8252937B2 (en) 2007-09-14 2012-08-28 Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
US8722894B2 (en) 2007-09-14 2014-05-13 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
RU2492170C9 (ru) 2007-11-14 2013-12-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Имидазо[1,2-а]пиридиновые производные и их применение в качестве положительных аллостерических модуляторов рецепторов mglur2
JP5693452B2 (ja) 2008-08-04 2015-04-01 シーエイチディーアイ ファウンデーション,インコーポレーテッド 特定のキヌレニン−3−モノオキシゲナーゼインヒビター、医薬組成物およびそれらの使用方法
JP5547194B2 (ja) 2008-09-02 2014-07-09 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 代謝型グルタミン酸受容体の調節因子としての3−アザビシクロ[3.1.0]ヘキシル誘導体
RU2517181C2 (ru) 2008-10-16 2014-05-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
MY153912A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 1, 2, 4,-triazolo[4,3-a[pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
BR112012003871A2 (pt) 2009-08-21 2015-09-08 Otsuka Pharma Co Ltd processo para a produção de composto de benzo[b][1,4]diazepina-2,4-diona
TWI481601B (zh) 2009-08-21 2015-04-21 Otsuka Pharma Co Ltd 含氮化合物及藥學組成物
MX2012008346A (es) 2010-01-25 2012-11-12 Chdi Foundation Inc Determinados inhibidores de cinurenina-3-monooxigenasa, composiciones farmceuticas y metodos de uso de los mismos.
CN103261195B (zh) 2010-11-08 2015-09-02 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
EP2661435B1 (en) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
PL2649069T3 (pl) 2010-11-08 2016-01-29 Janssen Pharmaceuticals Inc Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2
EP2701699B1 (en) 2011-04-28 2019-10-16 The Broad Institute, Inc. Inhibitors of histone deacetylase
US9193710B2 (en) 2011-08-29 2015-11-24 Sanford-Burnham Medical Research Institute Benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof
MX2014002459A (es) 2011-08-30 2014-04-10 Chdi Foundation Inc Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos.
SI2750677T1 (sl) 2011-08-30 2017-10-30 Chdi Foundation, Inc. Inhibitorji kinurenin-3-monooksigenaze, farmacevtski sestavki in postopki njihove uporabe
JP6337255B2 (ja) 2012-07-27 2018-06-06 ザ ブロード インスティテュート, インコーポレーテッドThe Broad Institute, Inc. ヒストンデアセチラーゼの阻害剤
EP2925292A1 (en) 2012-10-23 2015-10-07 F. Hoffmann-La Roche AG Mglu2/3 antagonists for the treatment of autistic disorders
US9914717B2 (en) 2012-12-20 2018-03-13 The Broad Institute, Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
KR20220049612A (ko) 2014-01-21 2022-04-21 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
HUE053734T2 (hu) 2014-01-21 2021-07-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait tartalmazó kombinációk és alkalmazásuk
KR20160143853A (ko) 2014-04-23 2016-12-14 에프. 호프만-라 로슈 아게 지적 장애의 치료를 위한 mglu2/3 길항제
CA2950952C (en) * 2014-06-10 2023-01-10 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof
CN106715421A (zh) 2014-07-17 2017-05-24 Chdi基金会股份有限公司 用于治疗hiv相关病症的方法和组合物
JP2017206438A (ja) * 2014-08-22 2017-11-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 テトラヒドロイミダゾ[1,5−d][1,4]オキサゼピン化合物(TETRAHYDROIMIDAZO[1,5−d][1,4]OXAZEPINECOMPOUND)
WO2018019755A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
WO2018019721A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
CA3125731A1 (en) 2018-01-12 2019-07-18 KDAc Therapeutics, Inc. Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer
CN110407740A (zh) * 2019-09-04 2019-11-05 上海毕得医药科技有限公司 一种3-溴-2-乙基吡啶的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE105839T1 (de) * 1989-03-23 1994-06-15 Pfizer Antiallergische mittel auf der basis von diazepin.
CA2386980C (en) 1999-10-15 2010-03-16 Geo Adam Benzodiazepine derivatives for use in acute or chronic neurological disorders
AU774451B2 (en) 1999-10-15 2004-06-24 F. Hoffmann-La Roche Ag Benzodiazepine derivatives

Also Published As

Publication number Publication date
JP2005522440A (ja) 2005-07-28
EP1474416B1 (en) 2007-09-26
BR0307474A (pt) 2004-11-09
PL372425A1 (en) 2005-07-25
WO2003066623A1 (en) 2003-08-14
PE20031011A1 (es) 2003-11-29
MXPA04007516A (es) 2004-11-10
IL163102A (en) 2011-07-31
EP1474416A1 (en) 2004-11-10
US6949542B2 (en) 2005-09-27
MY176608A (en) 2020-08-18
AR038481A1 (es) 2005-01-19
DE60316538T2 (de) 2008-08-21
DE60316538D1 (de) 2007-11-08
ZA200406032B (en) 2005-10-12
GT200300028A (es) 2004-06-11
ES2294264T3 (es) 2008-04-01
NO327697B1 (no) 2009-09-14
TWI326599B (en) 2010-07-01
US20030166639A1 (en) 2003-09-04
CA2474219C (en) 2010-04-13
DK1474416T3 (da) 2008-01-14
ATE374196T1 (de) 2007-10-15
NZ534122A (en) 2006-12-22
HRP20040678A2 (en) 2005-10-31
RU2004126945A (ru) 2005-06-27
PT1474416E (pt) 2007-12-27
TW200302730A (en) 2003-08-16
AU2003205695A1 (en) 2003-09-02
JP4077411B2 (ja) 2008-04-16
PA8565901A1 (es) 2003-09-05
RU2315764C2 (ru) 2008-01-27
KR20040081486A (ko) 2004-09-21
NO20043237L (no) 2004-08-02
CA2474219A1 (en) 2003-08-14
AU2003205695B2 (en) 2008-04-03
UY27654A1 (es) 2003-08-29
HK1078858A1 (zh) 2006-03-24
CN1633430A (zh) 2005-06-29
CN100497333C (zh) 2009-06-10
AU2003205695B8 (en) 2008-05-01

Similar Documents

Publication Publication Date Title
PL372425A1 (en) Dihydrobenzodiazepin-2-one-derivatives for the treatment of neurological disorders
IL169091A0 (en) Benzazepine derivatives for the treatment of neurological disorders
IL175055A0 (en) Combinations useful for the treatment of neuronal disorders
AU2003286567A8 (en) Methods for the treatment of skin disorders
ZA200401004B (en) Combination for the treatment of inflammatory disorders
SI1660057T1 (sl) Kombinirana terapija za zdravljenje okularnih neovaskularnih nepravilnosti
AU2002356525A1 (en) Substituted amines for the treatment of neurological disorders
IL209842A0 (en) Compounds for the treatment of metabolic disorders
AU2003249983A8 (en) Piperidines useful for the treatment of central nervous system disorders
IL176581A0 (en) Immunomodulatory compounds for the treatment of central nervous system disorders
AP2005003274A0 (en) Thiazole compounds for the treatment of neurodegenerative disorders
AU8187701A (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
AU2003274342A8 (en) Compositions for the treatment of autoimmune disorders
IL162485A0 (en) Compounds for the treatment of inflammatory disorders
AU2003228819A8 (en) Combinations for the treatment of inflammatory skin disorders
IL161267A0 (en) Combinations for the treatment of immunoinflammatory disorders
EP1617844A4 (en) TREATMENT OF NEUROLOGICAL DISEASES
EP1658072A4 (en) Compounds for the Treatment of Neurodegenerative Diseases
AU2003286728A8 (en) Compounds for the treatment of metabolic disorders
HRP20041160A2 (en) Novel combination for the treatment of airway disorders
AU2003274885A1 (en) Phenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain or gastrointestinal disorders
HRP20041159A2 (en) Combination for the treatment of airway disorders
GB0216097D0 (en) Treatment of proliferative disorders
AU2002322397A1 (en) Combination therapy for the treatment of neurological disorders
GB0213575D0 (en) Treatment for movement disorders